CLOSE to CURE Study

Not Applicable

Completed

• Conditions: Atrial Fibrillation
• Interventions: Procedure: Pulmonary vein isolation

• Registration Number: NCT02925624
• Lead Sponsor: AZ Sint-Jan AV

Brief Summary

Title: CLOSE-guided pulmonary vein isolation (PVI) as Cure for Paroxysmal Atrial Fibrillation ('CLOSE to CURE' study)

Design: This is a prospective, observational, single-center, unblinded, clinical 3-year study.

Background: In a population of paroxysmal atrial fibrillation (AF) 'CLOSE'-guided PVI, a new approach to obtain single-procedure durable PVI, has been shown to virtually eliminate recurrence of AF at 1 year follow-up with repetitive but discontinuous Holter monitoring.

Objectives: (1) To objectively compare atrial tachyarrhythmia (ATA) burden before and after 'CLOSE'-guided based PVI using continuous monitoring. (2) To assess ATA burden using continuous monitoring up to 3 years after ablation. (3) To identify baseline structural and electrical properties of the atria or procedural characteristics that predict 1-year and 3-year outcome.

Enrollment: Up to 100 subjects will be enrolled in this observational, prospective study.

Clinical Sites: 1 site.

Subject Population: Eligible patients are patients with paroxysmal high-burden AF who are planned for a 'CLOSE'-guided PV isolation. At the time of procedural planning we will ask the patient his/her consent for (1) implantation of a subcutaneous continuous loop recorder (sCLR), (2) a concise electrophysiological study at the time of PVI, (3) a transthoracic echocardiogram at the time of PVI and (4) collection of data during 3 years. Anti-arrhythmic drug treatment (ADT) and oral anticoagulation (OAC) will be given according the updated 2012 European society of Cardiology (ESC) guidelines on AF (Camm et al, European Heart Journal 2012) and the 2012 Heart rhythm society (HRS)/European Heart Rhythm association/European cardiac arrhythmic society Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation (Calkins et al, Heart Rhythm 2012).

Detailed Description

Not available

Study Timeline

• Study Start: 2015-12
• Study First Submitted: 2016-09-29
• Study First Submitted QC: 2016-10-04
• Study First Posted: 2016-10-06
• Primary Completion: 2021-03-31
• Study Completion: 2021-03-31
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-04
• Last Update Posted: 2021-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

1. Patients with symptomatic paroxysmal AF (history of self-terminating AF within 7 days or history of self-terminating AF with 1 or more cardioversions within 48 hours after onset), meeting following criteria at the out-patient clinic:

   • patient has at least 3 AF episodes in the last 3 months prior to the visit
   • AF episodes are symptomatic, and patient is drug-resistant (at least one class IC or III), or drug-intolerant (palpitations, fatigue, dyspnea, cardiomyopathy,...)
   • no advanced structural heart disease
   • patient has a CHA2DS2-VASc score of 0, 1, 2, 3 or 4

2. Signed Patient Informed Consent Form.

3. Age 18 years or older.

4. Able and willing to comply with all follow-up testing and requirements.

Exclusion Criteria

1. Persistent atrial fibrillation (history of AF>7days or history of cardioversion > 48h of AF)
2. Previous ablation for AF
3. LA antero-posterior diameter > 50 mm (parasternal long axis view , PLAX)
4. LVEF < 35% (ejection fraction)
5. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
6. Coronary artery bypass grafting (CABG) procedure within the last three months
7. Awaiting cardiac transplantation or other cardiac surgery
8. Documented left atrial thrombus on imaging
9. Diagnosed atrial myxoma
10. Women who are pregnant or breastfeeding
11. Acute illness or active systemic infection or sepsis
12. Unstable angina
13. Uncontrolled heart failure
14. Myocardial infarction within the previous two months
15. History of blood clotting or bleeding abnormalities
16. Contraindication to anticoagulation therapy (ie, heparin or warfarin)
17. Life expectancy less than 12 months
18. Enrollment in any other study evaluating another device or drug
19. Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CLOSE guided PVI and insertable cardiac monitor	Pulmonary vein isolation	-

Primary Outcome Measures

Name	Time	Method
Atrial tachyarrhythmia (ATA) burden before and after 'CLOSE'-guided based PVI	Continuous monitoring (24 hours loop recording)
Long-term evaluation of ATA burden after a single 'CLOSE' guided PVI procedure	Continuous monitoring (24 hours loop recording)

Secondary Outcome Measures

Name	Time	Method
Evaluating PV re-connection at redo procedure assessed by Lasso catheter	3 months to 3 years	Visual inspection of electrograms on the Lasso catheter will be performed to verify durable PV isolation or re-connection
Incidence of adverse events related to ablation	Baseline to 3 years
Freedom from stroke/transient ischemic attack (TIA)	Baseline to 3 years
Efficacy of CLOSE protocol ablation assessed by multiple-procedure freedom from ATA	1 month to 3 years	ATA include fibrillation, tachycardia, or flutter
Health economics and outcomes research assessed by quality of life using Short Form (SF-36v2) Health Survey	Recruitment to 3 years
Health economics and outcomes research assessed by number of hospitalization	Recruitment to 3 years	Includes total number of hospitalizations and unscheduled arrhythmia-related health care provider visits
Evaluating progression of scarring at redo procedure assessed by voltage mapping	3 months to 3 years	Point-by-point bipolar voltage mapping will be performed to quantify the amount of low voltage areas in the left atrium (LA)
Efficacy of CLOSE protocol ablation assessed by single-procedure freedom from documented atrial tachyarrhythmias (ATA)	1 month to 3 years	ATA include fibrillation, tachycardia, or flutter
Efficacy of CLOSE protocol ablation assessed by incidence of repeat ablation procedures	1 month to 3 years
Health economics and outcomes research assessed by quality of life using Symptomatic Questionnaire V3	Recruitment to 3 years

Trial Locations

Locations (1)

AZ Sint-Jan Hospital; 🇧🇪 Bruges, Belgium